90/4/4 : 89//7 : 90 /5 /. :. (Curcumin). ( 45 ) 40 : 500 4. ( 0 ).. 6 5. :... HER/neu :.. :..(-4). ( )...(-). Email: hematti@med.mui.ac.ir *... : 90 /5 / 9
(Curcumin) (Turmeric) Curcuma Longa. (-4) - () NF-kappa B (5) 9-..(5-7) () PPAR-g (0) AP- HER/neu (8-9) STAT EGFR. (-)... IL-/p70 IP-0 IL-/p40 INF alfa Eotaxin..(4)...()...(5).. Aloe Vera ( ) C Biafine.(6-9).(0) 90 /5 / 9
. 8 PTT PT 75000 /5 ALT AST.. 0 80-00. 4 ) 500 ( 6000.... (RTOG) Radiation Therapy Oncology Group. (5) 44 ± 0/7. 46/75 ± 0/5. 89 ( ) 90.. Non-inflammatory... ) (Gefitinib Trastuzumab. ) ( 90 /5 / 9
RTOG. Patchy 0 4.( ).( ). (P < 0/00) (P < 0/0) 0 0 4. HER/neu. 6 8 HERneu 7 0 4 0 8 0 8. HER/neu.(4 ).. ( 8 4 ). ( ) ( ).. 0 0 40.( ). 5 8 ER/PR 5 7 IHC ) HER/neu ( 90 /5 / 9 4
.5 0.5 0.95 0.95 0.7 0.5 0.4.9.5.05 0.55 0.5 قبل از درمان هفته اول هفته دوم هفته سوم هفته چهارم هفته پنجم هفته ششم 0..4 MRM BCS 0/75 /5 0/7 /6 0 0/75 HER/neu 0/85 /7 /9 /58 / /5 /. HER/neu.(-) 0..(6)... 50.(4) L-/p70 IL-/p40 INF alpha Eotaxin. IP-0 5 90 /5 / 9
. References. Burstein HJ, Harris JR, Morrow M. Malignant tumors of the breast. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 8 th ed. Philadelphia: Lippincott Williams & Wilkins; 008.p. 606-45.. Haffty BG, Perez CA, Perez CA. Early stage breast cancer. In: Halperin EC, Perez CA, Brady LW, Wazer DE, Freeman C, editors. Perez and Brady's principles and practice of radiation oncology. 5 th ed. Philadelphia: Lippincott Williams & Wilkins; 008. p. 75-9.. Khan FM. The physics of radiation therapy. rd ed. Philadelphia: Lippincott Williams & Wilkins; 00. 4. Hendee WR, Ibbott GS, Hendee EG. Radiation therapy physics. rd ed. New York: J. Wiley; 005. p. 44-. 5. Khan FM. Treatment planning in radiation oncology. nd ed. Philadelphia: Lippincott Williams & Wilkins; 007. 6. Williams MS, Burk M, Loprinzi CL, Hill M, Schomberg PJ, Nearhood K, et al. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys 996; 6(): 45-9. 7. Richardson J, Smith JE, McIntyre M, Thomas R, Pilkington K. Aloe vera for preventing radiationinduced skin reactions: a systematic literature review. Clin Oncol (R Coll Radiol) 005; 7(6): 478-84. 8. Fisher J, Scott C, Stevens R, Marconi B, Champion L, Freedman GM, et al. Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiationinduced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-. Int J Radiat Oncol Biol Phys 000; 48(5): 07-0. 9. Halperin EC, Gaspar L, George S, Darr D, Pinnell S. A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. CNS Cancer Consortium. Int J Radiat Oncol Biol Phys 99; 6(): 4-6. 0. Hemati S, Nasiri Motlagh B, Esnaashari O, Sarvizadeh M, Akbari M, Tajvidi M, et al. Topical Silver Sulfadiazine for Prevention of Acute Dermatitis during Irradiation for Breast Cancer: ESMO; 00.. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappab pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 005; (0): 7490-8.. Claria J, Romano M. Pharmacological intervention of cyclooxygenase- and 5-lipoxygenase pathways. Impact on inflammation and cancer.curr Pharm Des 005; (6): 4-47.. Mann JR, DuBois RN. Cyclooxygenase- and gastrointestinal cancer. Cancer J 004; 0(): 45-5. 4. Prescott SM. Is cyclooxygenase- the alpha and the omega in cancer? J Clin Invest 000; 05(): 5-. 5. Ramachandran C, You W. Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. Breast Cancer Res Treat 999; 54(): 69-78. 6. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ. Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 00; 84(): -6. 7. Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl- -methylcaffeate, and 6- phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 997; 57(7): 0-5. 8. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription- for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 006; 09: 5-69. 9. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL- 6-inducible STAT phosphorylation in human multiple myeloma cells. J Immunol 00; 7(7): 86-7. 0. Karin M, Liu Z, Zandi E. AP- function and regulation. Curr Opin Cell Biol 997; 9(): 40-6. 90 /5 / 9 6
. Xu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 00; 85(): G0- G0.. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 995; 6(8): 74-5.. Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A4 ١cells. Biochim Biophys Acta 994; 4(): 597-600. 4. Ryan JL, Heckler CE, Pentland AP, Morrow GR. Potential plasma biomarkers predicting radiation dermatitis in breast cancer patients. J Clin Oncol 00; 8(5): 944. 5. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 995; (5): 4-6. 6. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "ageold" solution. Cancer Lett 008; 67(): -64. 7 90 /5 / 9
Journal of Isfahan Medical School Original Article Vol 9, No 5, 4 th week, October 0 Received: 8..0 Accepted: 5.6.0 Abstract Clinical Evaluation of Oral Curcumin in Prevention of Acute Dermatitis in Breast Cancer Radiotherapy Simin Hemati MD, Armin Saeedi MD Background: Acute radiation induced dermatitis, has a history as long as breast radiotherapy. Although new techniques have reduced the onset of dermatitis in breast radiotherapy patients, no standard protocol exists for its prophylaxis. This study has evaluated Curcumin for prophylaxis of radiation induced dermatitis. Methods: 40 breast radiotherapy candidates randomly put in two equal groups, received oral capsules (four 500 mg capsules, times a day) filled with Curcumin or Placebo from days before to the last day of radiotherapy 6 weeks course. Dermatitis degree recorded in weekly visits. Findings: A faster increasing in mean degree of dermatitis was seen in placebo group. The difference was statistically significant in last two weeks of radiotherapy. No considerable side effect was reported. Patients age, type of surgery, hormone receptor and HER/neu status, did not affect curcumin group superiority in degree of radiation induced dermatitis. Conclusion: Oral curcumin is effective in prophylaxis of radiation induced dermatitis in breast cancer radiation. Keywords: Breast cancer, Radiotherapy, Dermatitis, Curcumin. * This paper is derived from a speciality thesis in Isfahan University of Medical Sciences. Assistant Professor, Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Resident, Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Corresponding Author: Simin Hemati MD, Email: hematti@med.mui.ac.ir 90 /5 / 9 8